Research Abstract
Dr. Barthel’s multidisciplinary research focuses on melanoma and non-melanoma skin cancers, immune checkpoint receptor biology, immunotherapy, tumor cell metastasis, leukocyte homing, and the glycobiology of malignant versus normal tissues. His research incorporates advanced tools and methodologies for both examining and targeting glycostructural moieties expressed on various cancer and immune cell subsets. As part of these investigations, his lab employs established human and murine melanoma lines, patient melanoma biospecimens, primary immune cells, CRISPR-based gene knockout and knockdown transgenic tumor lines, and murine models of human cancer. Dr. Barthel’s goals are to leverage new glycan-based modifying strategies to enhance therapeutic benefit in cancer patients. He is a funded Principal Investigator on several NIH grants from the NCI and serves as Co-Director of the Harvard Program of Glyco-Immunology and Oncology (PGIO).
